NCT02626520View on ClinicalTrials.gov

Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla

PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 11, 2016

Primary Completion Date

September 20, 2016

Study Completion Date

September 14, 2017

Conditions
Ductal Adenocarcinoma of PancreasAdenocarcinoma of Ampulla
Interventions
DRUG

Gemcitabine and nanoparticle albumin bound paclitaxel

Gemcitabine and nab-paclitaxel given every 14 days x 4 cycles

DRUG

5-fluorouracil and irinotecan

FOLFIRI.3 given every 14 days x 4 cycles

RADIATION

Preoperative chemoradiation

Pre-operative chemoradiation to 40 Gy in 20 fractions

PROCEDURE

Definitive resection

Definitive surgical resection of primary tumor

Trial Locations (1)

55805

Essentia Health Cancer Center, Duluth

Sponsors

Lead Sponsor

Essentia Health
All Listed Sponsors
lead

Essentia Health

OTHER

NCT02626520 - Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla | Biotech Hunter | Biotech Hunter